,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,U82695.5,,ENSG00000214897,,X,153395640-153401420,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,35,epididymis: 5.8;ovary: 4.7;testis: 10.9,fallopian tube: 0.2,Not detected,,
1,C4BPB,C4BP,ENSG00000123843,Complement component 4 binding protein beta,1,207088842-207099993,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA051620,Approved,,,,,Tissue enriched,Group enriched,16,liver: 241.3;ovary: 52.0,placenta: 8.9,Group enriched,15.0,CACO-2: 94.2;HeLa: 31.3;Hep G2: 101.7
2,GPR88,,ENSG00000181656,G protein-coupled receptor 88,1,100538137-100542018,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at transcript level,HPA007488,,Approved,,,,Tissue enriched,Group enriched,11,breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4,prostate: 0.6,Group enriched,8.0,HSkMC: 1.1;SCLC-21H: 2.3
3,MCF2,"ARHGEF21, DBL",ENSG00000101977,MCF.2 cell line derived transforming sequence,X,139581770-139708227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,11,adrenal gland: 38.3;cerebral cortex: 8.7;epididymis: 15.0;ovary: 12.9;seminal vesicle: 24.0;testis: 34.6,prostate: 2.0,Cell line enriched,12.0,U-251 MG: 30.6
4,HTR1A,"5-HT1A, ADRB2RL1, ADRBRL1",ENSG00000178394,5-hydroxytryptamine receptor 1A,5,63960356-63962507,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018073,Uncertain,,,,,Not detected,Group enriched,10,cerebral cortex: 1.9;ovary: 3.9,testis: 0.2,Group enriched,16.0,NTERA-2: 1.6;SCLC-21H: 1.5
5,FSHR,"FSHRO, LGR1, ODG1",ENSG00000170820,Follicle stimulating hormone receptor,2,48962157-49154537,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Group enriched,9,ovary: 2.5;testis: 4.3,gallbladder: 0.3,Not detected,,
6,NXPH2,NPH2,ENSG00000144227,Neurexophilin 2,2,138670772-138780348,Predicted secreted proteins,Evidence at transcript level,HPA034759,Approved,,,,,Mixed,Group enriched,9,cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0,endometrium: 0.9,Cell line enhanced,,AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7
7,PROK1,"EGVEGF, PK1, PRK1",ENSG00000143125,Prokineticin 1,1,110451200-110457354,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,9,ovary: 239.3;placenta: 75.8;testis: 119.4,seminal vesicle: 15.2,Cell line enriched,9.0,ASC diff: 16.3
8,SPRR2F,,ENSG00000244094,Small proline rich protein 2F,1,153112114-153113515,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,9,esophagus: 167.0;ovary: 83.7;tonsil: 63.0,testis: 11.8,Cell line enriched,9.0,K-562: 2.4
9,SIGLEC11,,ENSG00000161640,Sialic acid binding Ig like lectin 11,19,49948985-49961172,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA060278,Approved,,,,,Mixed,Group enriched,7,ovary: 80.0;spleen: 31.7,adrenal gland: 8.1,Cell line enriched,15.0,HEL: 9.4
10,ZIM2,ZNF656,ENSG00000269699,Zinc finger imprinted 2,19,56774552-56840729,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071856,,,Approved,Nuclear speckles<br>Cytosol,,Not detected,Group enriched,7,adrenal gland: 5.8;cerebral cortex: 5.1;ovary: 9.9;placenta: 6.8;testis: 7.7,endometrium: 1.0,Cell line enhanced,,BEWO: 4.7;Hep G2: 4.0;NTERA-2: 1.6;RH-30: 1.6;U-2 OS: 1.2
11,ANO4,"FLJ34221, FLJ34272, FLJ35277, TMEM16D",ENSG00000151572,Anoctamin 4,12,100717526-101128641,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA053412,Uncertain,,,,Renal cancer:5.48e-5 (favourable),Mixed,Group enriched,6,"adrenal gland: 17.6;cerebral cortex: 10.0;cervix, uterine: 12.6;endometrium: 8.4;ovary: 10.9;prostate: 11.7;seminal vesicle: 11.4",testis: 2.0,Cell line enhanced,,fHDF/TERT166: 14.2;SK-MEL-30: 13.3;TIME: 26.1;WM-115: 10.6
12,GSTM5,,ENSG00000134201,Glutathione S-transferase mu 5,1,109712255-109775428,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA048652, HPA055972, HPA055973",Approved,,Approved,Cytokinetic bridge<br>Cytosol,,Mixed,Group enriched,6,breast: 845.2;ovary: 221.0,fallopian tube: 84.6,Group enriched,8.0,fHDF/TERT166: 12.9;HHSteC: 5.7;HSkMC: 5.3
13,NR5A1,"AD4BP, ELP, FTZ1, FTZF1, hSF-1, SF-1",ENSG00000136931,Nuclear receptor subfamily 5 group A member 1,9,124481236-124507430,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Group enriched,6,adrenal gland: 137.7;ovary: 36.3;spleen: 151.6,testis: 19.6,Group enriched,31.0,HEL: 73.5;Hep G2: 36.2;K-562: 17.7
14,SLC4A3,"AE3, SLC2C",ENSG00000114923,Solute carrier family 4 member 3,2,219627327-219641980,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA063498,,,Approved,Nucleoplasm,Urothelial cancer:4.12e-4 (unfavourable),Expressed in all,Group enriched,6,cerebral cortex: 30.0;heart muscle: 119.1;ovary: 47.7,testis: 10.9,Mixed,,
15,ASIP,"AGTIL, ASP",ENSG00000101440,Agouti signaling protein,20,34194569-34269344,Predicted secreted proteins,Evidence at protein level,HPA048636,Uncertain,,Supported,Vesicles,,Mixed,Group enriched,5,epididymis: 18.1;ovary: 7.4;skin: 5.7,breast: 2.0,Cell line enhanced,,CACO-2: 2.6
16,KCNT1,"KCa4.1, KIAA1422, SLACK, Slo2.2",ENSG00000107147,Potassium sodium-activated channel subfamily T member 1,9,135702185-135795508,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA059880,Uncertain,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 11.6;ovary: 3.9;skeletal muscle: 3.8;spleen: 6.8,testis: 1.2,Cell line enhanced,,RPMI-8226: 1.2;SCLC-21H: 3.0
17,MTUS2,"CAZIP, ICIS, KIAA0774, TIP150",ENSG00000132938,Microtubule associated tumor suppressor candidate 2,13,28820348-29505947,Predicted intracellular proteins,Evidence at protein level,"HPA031473, HPA031474, HPA031475",Enhanced,,Supported,Microtubules<br>Cytokinetic bridge,,Mixed,Group enriched,5,heart muscle: 33.4;ovary: 9.5,cerebral cortex: 4.2,Cell line enhanced,,HaCaT: 11.7;HeLa: 3.7
18,USP6,"HRP1, Tre-2, TRE17, Tre2, TRESMCR",ENSG00000129204,Ubiquitin specific peptidase 6,17,5116438-5175034,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046969,,,Uncertain,Vesicles,,Tissue enriched,Group enriched,5,ovary: 3.5;skeletal muscle: 7.5;testis: 17.1,smooth muscle: 1.8,Mixed,,
